Navigation Links
Amgen Backs States' Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
Date:1/25/2013

THOUSAND OAKS, Calif., Jan. 25, 2013 /PRNewswire/ -- In conjunction with our oncology biosimilars partner Actavis' announcement earlier today of our four oncology biosimilars products, Amgen (NASDAQ: AMGN) today stated that it supports state biosimilars initiatives that focus on sound science and patient safety. As a biotech company developing both innovator biologics and biosimilars, Amgen believes that patient safety does not stop at drug approval. 

"Amgen endorses state policies that would put patients first and, in doing so, increase confidence in the biosimilar pathway. It is important to have consistent policies in place at the federal and state level," said Scott Foraker , vice president and general manager of biosimilars at Amgen. 

States' efforts to create safe substitution rules for interchangeable biologics will help accelerate the successful implementation of the U.S. biosimilars pathway. Regulatory authorities in Europe and the U.S. have emphasized the need for long-term safety monitoring of biologics. Biologic medicines are different than traditional chemical drugs in several important ways. Biologics are so complex that they can usually only be made by a living cell.  In fact, when made by different manufacturers, they differ from each other.  They are also very large compared to chemical drugs and can be more sensitive to storage and handling. As a result biologic medicines have the potential to cause an unwanted immune response, which can show up months after taking the medicine. This emphasizes why Amgen believes state pharmacy acts must enhance safety monitoring of substituted biologics.

Amgen is helping educate state policymakers on these considerations to ensure that physicians, patients and pharmacists share important information about biologic substitution.   To provide appropriate safeguards, patient medical records must accurately reflect the biologic medicine a patient receives, by requiring that physicians be informed within a reasonable time after an interchangeable biologic substitution has occurred. Furthermore physicians and pharmacists must work collaboratively to serve patients and protect patient safety.

Amgen believes that a notification process that does not impose an undue burden on the pharmacist is in the patient's best interest. Some proposed state legislation includes these important safeguards such as after-the-fact notification to facilitate accurate record keeping and attribution of adverse events. The company said it is critical that efficient measures close the gap in biologic traceability that could otherwise be created.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss , 805-313-6151 (media)
Arvind Sood , 805-447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgens Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
2. Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
3. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
4. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
5. Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
6. Amgen Supports Assistance for Patients Affected by Hurricane Sandy
7. Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
8. Amgen To Present At The Morgan Stanley Global Healthcare Conference
9. Amgen To Present At The Baird Healthcare Conference
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced further details of three new ... aspects of Lewy body dementia, a disease affecting ... out of the three studies were recently initiated ... this quarter. In addition, the Company reported financial ...
(Date:2/9/2016)... SAN FRANCISCO , February 9, 2016 ... a biotechnology company focused on developing products for Regenerative ... will be a featured presenting company at Source Capital ... place on February 10-11, 2016 in New ... given on Wednesday, February 10, 2016 at 12:30 pm ...
(Date:2/9/2016)... -- The global prefilled syringes market accounted for $3,905.1 ... grow with a CAGR of 12.9% during 2015-2020. Among ... the global prefilled syringes market, with 90.1% share in ... The global market of prefilled syringes is up surging ... increasing demand for vaccines, increasing prevalence of chronic and ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... ... today the continuation of the ‘Pay It Forward’ program into 2016. BioPlus partners ... at our specialty pharmacy. , “Since our Pay It Forward program began, ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has raised ... of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of Iowa, ...
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, Inc., ... introduction of the newly designed, innovative shoulder wrap. The newly designed shoulder ... for the injured arm and shoulder to promote faster healing. It is highly ...
(Date:2/9/2016)... ... , ... i2i Systems, an early innovator and developer of population health management ... KLAS report, Population Health Management 2015: How Far Can Your Vendor Take You? ... (PHM). The latest KLAS Report, leveraging over 200 user interviews, shines a light ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... its newly redesigned website, federallabs.org . The site houses a wealth of ... available federal technologies through the process called technology transfer (T2). As a network ...
Breaking Medicine News(10 mins):